Introduction
MULTIPLE MYELOMA (MM)
In transplant-eligible patients with newly diagnosed multiple myeloma (MM), induction therapy followed by peripheral blood stem cell (PBSC) collection with granulocyte-colony-stimulating factor (G-CSF), high-dose chemotherapy (HDCT) with melphalan and autologous blood stem cell transplantation (ABSCT) is a standard-of-care [While a single treatment with HDCT/ABSCT prolongs overall survival (OS) [A variety of factors, such as higher age, melphalan-containing induction or previous radiotherapy involving haematopoietic bone marrow are associated with impaired PBSC collection results or increased rates of collection failure [Anti-CD38 monoclonal antibodies (mAb), such as daratumumab and isatuximab, significantly improve efficacy and outcomes after induction therapy [